ESR1 and breast cancer: We found that derivative 2 displayed a higher bioavailability compared to RSV and was the most active in exerting anti-inflammatory and anti-proliferative effects; this derivative was able to induce cell cycle arrest and apoptosis of estrogen receptor positive (ER+) MCF7 and estrogen receptor negative (ER-) MDA-MB231 breast cancer cells.